$AFMD ICYMI: Affimed spinout #Amphivena with its lead T-cell engager #AMV564 (once partnered &amp; AFMD developed 4 $JNJ) after initial success in hematological trials now shows success in  #solid tumors 2 including a first CR in #ovarian cancer https://t.co/F3IqTkl36d https://t.co/vihRTfbLmQ